Race Oncology Ltd has released a press release.
Prospectus
Filed with ASX ·
On 6ix: 6ix.com/news/prospectus-199
6ix hasn’t read this filing yet.
Earlier from Racura Oncology
- Placement closes oversubscribed-Bonus Option Issue launched
- Race investor briefing & updated presentation
- Race Initiates Heart Safety Preclinical Study for Bisantrene
- Second independent study shows Bisantrene inhibits FTO
- Race Strategic Update March 2021
Later from Racura Oncology
- Contract to Commence Phase 2 Extramedullary AML Trial
- Race Executes Key Contract for Israel Phase 2 AML Trial
- Race executes Israel AML Phase 2 Trial Contract
- First Patient Dosed in Phase 1b/2 AML Trial
- Zantrene highly effective in Melanoma preclinical study
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology